Source comparison
MOTS-c Animal vs Human Research: Comparison Breakdown
Effect Magnitude 30–50% improvement in glucose tolerance and endurance 8–15% improvement in insulin sensitivity and VO2 max Animal models demonstrate biological ceiling; human results reflect realistic clinical effect sizes constrained by slower metabolic turn
This comparison does not assign a generated winner or score.
- Effect Magnitude
- 30–50% improvement in glucose tolerance and endurance
- 8–15% improvement in insulin sensitivity and VO2 max
- Animal models demonstrate biological ceiling; human results reflect realistic clinical effect sizes constrained by slower metabolic turnover
- Time to Observable Effect
- 48 hours to 7 days
- 8–12 weeks
- Species metabolic rate difference. Mice complete mitochondrial remodeling cycles 7–10× faster than humans
- Optimal Dose (per kg)
- 5–15 mg/kg intraperitoneally
- 0.07–0.14 mg/kg subcutaneously (5–10mg total for 70kg adult)
- Direct dose translation fails due to absorption route differences; human subcutaneous bioavailability requires lower nominal doses
- Primary Mechanism
- AMPK activation → immediate metabolic shift
- AMPK activation → delayed mitochondrial biogenesis
- Mechanism identical; timeline diverges because human mitochondrial turnover takes 4–6 weeks vs 5–7 days in rodents
- Best Responder Profile
- All subjects show response regardless of baseline
- Strongest response in metabolically impaired individuals (prediabetes, insulin resistance)
- MOTS-c corrects dysfunction more effectively than it enhances optimised systems. Human variability reflects baseline metabolic health
- Adverse Events
- None reported at standard doses
- Injection site reactions in 15–20% at doses above 5mg; no systemic adverse events
- Human tolerance consistent with other mitochondrial peptides; site reactions dose-dependent and self-limiting